Background: Intracranial atherosclerotic disease (ICAD) is an important cause of ischemic stroke (IS) and endothelial dysfunction plays a critical role in its onset and progression. Endothelial progenitor cells (EPCs) and endothelial production of angiogenic growth factors (AGFs) may play an essential role in this process. This study investigated the association of EPCs and AGFs with ICAD severity. Methods: A total of 42 patients who had experienced a transient ischemic attack (TIA) or IS attributable to symptomatic ICAD were included. Clinical and neurosonological evaluations were conducted between 2.4 and 8.7 years after the initial cerebrovascular event. Severe ICAD was defined as the presence of at least 1 severe intracranial stenosis, and extensive ICAD as 3 or more intracranial stenoses. Blood samples were obtained to determine EPC levels using flow cytometry (CD34+KDR+ cells), and the plasma levels of several growth factors were assessed with a protein array (Searchlight®). Twenty-two individuals without cerebrovascular disease and with normal ultrasonographic examination were also included. Results: No difference in the count of circulating EPCs was found between patients and controls, and a moderate increase in the number of EPCs/ml was noted in patients with extensive ICAD (p = 0.05). Patients presented decreased levels of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF-BB) compared with controls (p = 0.002, p = 0.079 and p = 0.061, respectively). Higher levels of FGF, VEGF and PDGF-BB were found in patients with severe ICAD (p = 0.007, p = 0.07 and p = 0.07, respectively), but there was no correlation between any AGFs and EPCs. Conclusions: Symptomatic ICAD patients have decreased levels of AGFs with no correlation to the number of circulating EPCs, while patients with severe ICAD have higher levels of EPCs, FGF, VEGF and PDGF-BBs. This suggests that reduced EPC and proangiogenic factor production capacity is implicated in ICAD pathogenesis, while the more severe forms of chronic brain hypoperfusion in ICAD patients might stimulate EPC mobilization and AGF production.

Keywords:
Endothelial progenitor cells, Growth factors, Intracranial stenosis, Stenosis severity, Atherosclerosis
1.
Sacco R, Kargman DE, Quiong Gu, Zamanillo MC: Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995;26:14–20.
2.
Wong KS, Huang YN, Gao S, Lam WWM, Chan YL, Kay R: Intracranial stenosis in Chinese patients with acute stroke. Neurology 1998;50:812–813.
3.
Thomas GN, Chen XY, Lin JW, Tomlinson B, Lam WW, Liu R, et al: Middle cerebral artery stenosis increased the risk of vascular disease mortality among type 2 diabetic patients. Cerebrovasc Dis 2008;25:261–267.
4.
Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al, Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–1316.
5.
Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al: Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993–1003.
6.
Roquer J, Segura T, Serena J, Castillo J: Endothelial dysfunction, vascular disease and stroke: the ARTICO study. Cerebrovasc Dis 2009;27(suppl 1):25–37.
7.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.
8.
Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593–600.
9.
Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, Penalba A, Ribó M, Alvarez-Sabín J, et al: Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvasc Res 2010;80:317–323.
10.
Rehman J, Li J, Orschell CM, March KL: Peripheral blood ‘endothelial progenitor cells’ are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003;107:1164–1169.
11.
Zhang Y, Ingram DA, Murphy MP, Saadatzadeh MR, Mead LE, Prater DN, et al: Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2009;296:1675–1682.
12.
Lasala GP, Silva JA, Kusnick BA, Minguell JJ: Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a phase I study. Cardiovasc Revasc Med 2011;12:29–34.
13.
Ghani U, Shuaib A, Salam A, Nasir A, Shuaib U, Jeerakathil T, et al: Endothelial progenitor cells during cerebrovascular disease. Stroke 2005;36:151–153.
14.
Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, Nagatsuka K, et al: Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation 2004;109:2972–2975.
15.
Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, et al: Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 2008;39:69–74.
16.
Lau KK, Chan YH, Yiu KH, Li SW, Tam S, Lau CP, et al: Burden of carotid atherosclerosis in patients with stroke: relationships with circulating endothelial progenitor cells and hypertension. J Hum Hypertens 2007;21:445–451.
17.
Arenillas JF, Molina CA, Chacón P, Rovira A, Montaner J, Coscojuela P, et al: High lipoprotein (a), diabetes and the extent of symptomatic intracranial atherosclerosis. Neurology 2004;63:27–32.
18.
Arenillas JF, Álvarez-Sabín J, Molina CA, Chacón P, Montaner J, Rovira A, et al: C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke 2003;34:2463–2468.
19.
Arenillas JF, Massot A, Alvarez-Sabín J, Fernandez-Cadenas I, del Rio-Espinola A, Chacon P, et al: C-reactive protein gene C1444T polymorphism and risk of recurrent ischemic events in patients with symptomatic intracranial atherostenoses. Cerebrovasc Dis 2009;28:95–102.
20.
Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, et al: Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 2004;24:1246–1252.
21.
George J, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A: Comparative analysis of methods for assessment of circulating endothelial progenitor cells. Tissue Eng 2006;12:331–335.
22.
Fadini GP, Baesso I, Albiero M, Sartore S, Agostini C, Avogaro A: Technical notes on endothelial progenitor cells: ways to escape from the knowledge plateau. Atherosclerosis 2008;197:496–503.
23.
Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, et al: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005;111:2981–2987.
24.
Liman TG, Endres M: New vessels after stroke: postischemic neovascularization and regeneration. Cerebrovasc Dis 2012;33:492–499.
25.
Fadini GP, de Kreutzenberg S, Agostini C, Boscaro E, Tiengo A, Dimmeler S, et al: Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis 2009;207:213–219.
26.
Cesari F, Nencini P, Nesi M, Caporale R, Giusti B, Abbate R, et al: Bone marrow-derived progenitor cells in the early phase of ischemic stroke: relation with stroke severity and discharge outcome. J Cereb Blood Flow Metab 2009;29:1983–1990.
27.
Bogoslovsky T, Chaudhry A, Latour L, Maric D, Luby M, Spatz M, et al: Endothelial progenitor cells correlate with lesion volume and growth in acute stroke. Neurology 2010;75:2059–2062.
28.
Miller-Kasprzak E, Jagodziński PP: Endothelial progenitor cells as a new agent contributing to vascular repair. Arch Immunol Ther Exp (Warsz) 2007;55:247–259.
29.
Bulut D, Albrecht N, Imöhl M, Günesdogan B, Bulut-Streich N, Börgel J, et al: Hormonal status modulates circulating endothelial progenitor cells. Clin Res Cardiol 2007;96:258–263.
30.
Rafat N, Beck GCh, Peña-Tapia PG, Schmiedek P, Vajkoczy P: Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke 2009;40:432–438.
31.
Ni G, Liu W, Huang X, Zhu S, Yue X, Chen Z, et al: Increased levels of circulating SDF-1α and CD34(+) CXCR4(+) cells in patients with moyamoya disease. Eur J Neurol 2011;18:1304–1309.
32.
Akita T, Murohara T, Ikeda H, Sasaki K, Shimada T, Egami K, et al: Hypoxic preconditioning augments efficacy of human endothelial progenitor cells for therapeutic neovascularization. Lab Invest 2003;83:65–73.
33.
Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575–583.
34.
Guo H, Huang L, Cheng M, Jin X, Zhao Y, Yi M: Serial measurement of serum basic fibroblast growth factor in patients with acute cerebral infarction. Neurosci Lett 2006;393:56–59.
35.
Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, et al: Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996;132:1177–1188.
36.
Sobrino T, Pérez-Mato M, Brea D, Rodríguez-Yáñez M, Blanco M, Castillo J: Temporal profile of molecular signatures associated with circulating endothelial progenitor cells in human ischemic stroke. J Neurosci Res 2012;90:1788–1793.
37.
Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1–E7.
38.
Chang EI, Loh SA, Ceradini DJ, Chang EI, Lin SE, Bastidas N, et al: Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1α stabilization during ischemia. Circulation 2007;116:2818–2829.
39.
Chu K, Jung KH, Lee ST, Park HK, Sinn DI, Kim JM, et al: Circulating endothelial progenitor cells as a new marker of endothelial dysfunction or repair in acute stroke. Stroke 2008;39:1441–1447.
40.
Sobrino T, Hurtado O, Moro MA, Rodríguez-Yáñez M, Castellanos M, Brea D, Moldes O, et al: The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke 2007;38:2759–2764.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.